• For inclusion in Cohort 1 patients should have adrenocortical carcinoma(ACC), or malignant pheochromocytoma/paraganglioma (MPP), as defined below for Cohorts 2A and 3A.

• For inclusion in Cohorts 2A and 2B patients should have histologically confirmed (at primary diagnosis) unresectable locally advanced or metastatic adrenocortical carcinoma.

• For inclusion in Cohorts 3A and 3B patients should have histologically confirmed (at primary diagnosis) unresectable malignant (defined as metastatic disease, i.e. presence of chromaffin tissue in non-chromaffin organs) pheochromocytoma/paraganglioma, and RECIST defined progression should have been documented during a maximum of an 18-months period.

• Patients with an age ≥ 18 years old.

• Patients who are human leukocyte antigen (HLA)-A2 positive.

• Patients with an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.

• Patients with a life expectancy \> 4 months as judged by their treating physician.

• Patients with at least one measurable lesion according to RECIST 1.1.

• Males or non-pregnant, non-lactating, females.

⁃ Patients willing and able to comply with the scheduled visits, treatment plan, laboratory tests, and other study procedures indicated in the protocol.

⁃ Patients having received the information sheet and who have provided written informed consent prior to any study-related procedures.